University of California San Francisco

Kratz Lab Publications

Kratz Lab Publications
  1. Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial.
    2025 | PubMed
  2. An international, multicenter, prospective randomized trial of adjuvant chemotherapy for stage Ia-IIa non-small cell lung cancer identified as high-risk by a 14-gene molecular assay.
    2025 | An international, multicenter, prospective randomized trial of adjuvant chemotherapy for stage Ia-IIa non-small cell lung cancer identified as high-risk by a 14-gene molecular assay.
    ' href="https://researcherprofiles.org/profile/623964000">UCSF Research Profile
  3. Letter: Commentary: Trans-Sternal Multilevel Corpectomy for Cervicothoracic Renal Cell Metastasis: 2-Dimensional Operative Video.
    2024 | PubMed
  4. Abstract C025: Identification of cell-cell signaling programs across the tumor-tumor microenvironment ecosystem and associated with clinical status in neoadjuvant osimertinib treated patient samples revealed by spatial profiling.
    2024 | Abstract C025: Identification of cell-cell signaling programs across the tumor-tumor microenvironment ecosystem and associated with clinical status in neoadjuvant osimertinib treated patient samples revealed by spatial profiling.
    ' href="https://researcherprofiles.org/profile/565917262">UCSF Research Profile
  5. 8P Precision medicine drug testing platform to guide the treatment of EML4-ALK fusion lung cancers.
    2024 | 8P Precision medicine drug testing platform to guide the treatment of EML4-ALK fusion lung cancers.
    ' href="https://researcherprofiles.org/profile/559740942">UCSF Research Profile
  6. Precision medicine-based platform to guide the treatment of EML4-ALK driven lung cancers and other NSCLC in real time.
    2024 | Precision medicine-based platform to guide the treatment of EML4-ALK driven lung cancers and other NSCLC in real time.
    ' href="https://researcherprofiles.org/profile/536117515">UCSF Research Profile
  7. Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.
    2024 | PubMed
  8. A prognostic model for use before elective surgery to estimate the risk of postoperative pulmonary complications (GSU-Pulmonary Score): a development and validation study in three international cohorts.
    2024 | PubMed
  9. Trans-Sternal Multilevel Corpectomy for Cervicothoracic Renal Cell Metastasis: 2-Dimensional Operative Video.
    2024 | PubMed
  10. Quantitative Polymerase Chain Reaction and Precision Medicine.
    2023 | Quantitative Polymerase Chain Reaction and Precision Medicine.
    ' href="https://researcherprofiles.org/profile/521240421">UCSF Research Profile
  11. Treatments for dengue: a Global Dengue Alliance to address unmet needs.
    2023 | PubMed
  12. PET Standardized Uptake Value May Influence Surgical Planning for Clinical Stage IA Non-Small Cell Lung Cancer.
    2023 | PubMed
  13. Phase II trial of neoadjuvant osimertinib for surgically resectable EGFR -mutated non-small cell lung cancer.
    2023 | Phase II trial of neoadjuvant osimertinib for surgically resectable EGFR -mutated non-small cell lung cancer.
    ' href="https://researcherprofiles.org/profile/420600753">UCSF Research Profile
  14. Transcriptional space-time mapping identifies concerted immune and stromal cell patterns and gene programs in wound healing and cancer.
    2023 | PubMed
  15. 287 Genomic and Immunologic Characterization of Lung Adenocarcinoma in Never Smokers vs. Smokers.
    2023 | 287 Genomic and Immunologic Characterization of Lung Adenocarcinoma in Never Smokers vs. Smokers.
    ' href="https://researcherprofiles.org/profile/420600562">UCSF Research Profile
  16. Comparative genomics between matched solid and lepidic portions of semi-solid lung adenocarcinomas.
    2023 | PubMed
  17. SARS-CoV-2 infection of airway organoids reveals conserved use of Tetraspanin-8 by Ancestral, Delta, and Omicron variants.
    2023 | PubMed
  18. Tracheal Reconstruction Using Endotracheal Stent and Pectoralis Major Muscle Flap.
    2022 | PubMed
  19. Outcomes of gynecologic cancer surgery during the COVID-19 pandemic: an international, multicenter, prospective CovidSurg-Gynecologic Oncology Cancer study.
    2022 | PubMed
  20. Discovering dominant tumor immune archetypes in a pan-cancer census.
    2021 | PubMed
  21. Genetic and immunologic features of recurrent stage I lung adenocarcinoma.
    2021 | PubMed
  22. Death following pulmonary complications of surgery before and during the SARS-CoV-2 pandemic.
    2021 | PubMed
  23. Perioperative Lung Resection Outcomes After Implementation of a Multidisciplinary, Evidence-based Thoracic ERAS Program.
    2021 | PubMed
  24. Multiomic Characterization of Stage I Lung Adenocarcinoma Reveals Distinct Genetic and Immunologic Features of Recurrent Disease.
    2021 | Multiomic Characterization of Stage I Lung Adenocarcinoma Reveals Distinct Genetic and Immunologic Features of Recurrent Disease.
    ' href="https://researcherprofiles.org/profile/242616642">UCSF Research Profile
  25. Effect of COVID-19 pandemic lockdowns on planned cancer surgery for 15 tumour types in 61 countries: an international, prospective, cohort study.
    2021 | PubMed
  26. P26.02 A Phase II Trial of Neoadjuvant Osimertinib for Surgically Resectable EGFR-Mutant Non-Small Cell Lung Cancer: Updated Results.
    2021 | P26.02 A Phase II Trial of Neoadjuvant Osimertinib for Surgically Resectable EGFR-Mutant Non-Small Cell Lung Cancer: Updated Results.
    ' href="https://researcherprofiles.org/profile/239466115">UCSF Research Profile
  27. SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study.
    2021 | PubMed
  28. Improved outcomes and staging in non-small-cell lung cancer guided by a molecular assay.
    2021 | PubMed
  29. SARS-CoV-2 infection and venous thromboembolism after surgery: an international prospective cohort study.
    2021 | PubMed
  30. Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early-Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit From Adjuvant Chemotherapy.
    2021 | PubMed
  31. SARS-CoV-2 infection studies in lung organoids identify TSPAN8 as novel mediator.
    2021 | PubMed
  32. Resectability, Recurrence, and Risk Stratification of Giant Solitary Fibrous Tumors in the Thoracic Cavity.
    2021 | PubMed
  33. Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study.
    2021 | PubMed
  34. Bioinformatic Approaches to Validation and Functional Analysis of 3D Lung Cancer Models.
    2021 | PubMed
  35. Commentary: Cardiothoracic surgery training: Global challenges without universal solutions.
    2021 | PubMed
  36. MO01.13 Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit from Adjuvant Chemotherapy.
    2021 | MO01.13 Molecular Risk Stratification is Independent of EGFR Mutation Status in Identifying Early Stage Non-Squamous Non-Small Cell Lung Cancer Patients at Risk for Recurrence and Likely to Benefit from Adjuvant Chemotherapy.
    ' href="https://researcherprofiles.org/profile/174728900">UCSF Research Profile
  37. Elective Cancer Surgery in COVID-19-Free Surgical Pathways During the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study.
    2020 | PubMed
  38. Delaying surgery for patients with a previous SARS-CoV-2 infection.
    2020 | PubMed
  39. Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing.
    2020 | PubMed
  40. Pulmonary Embolus of Benign Liver Tissue Following Partial Hepatectomy.
    2020 | Pulmonary Embolus of Benign Liver Tissue Following Partial Hepatectomy.
    ' href="https://researcherprofiles.org/profile/151837278">UCSF Research Profile
  41. Comparison of Conventional TNM and Novel TNMB Staging Systems for Non-Small Cell Lung Cancer.
    2019 | PubMed
  42. Esophagectomy Outcomes after Implementation of an Enhanced Recovery after Surgery Program.
    2019 | Esophagectomy Outcomes after Implementation of an Enhanced Recovery after Surgery Program.
    ' href="https://researcherprofiles.org/profile/79291272">UCSF Research Profile
  43. MA06.09 Timing of Driver Mutation Development and the Genetic Evolution of Semi-Solid Lung Nodules into Early NSCLC.
    2019 | MA06.09 Timing of Driver Mutation Development and the Genetic Evolution of Semi-Solid Lung Nodules into Early NSCLC.
    ' href="https://researcherprofiles.org/profile/79291896">UCSF Research Profile
  44. P1.14-58 A Phase II Study to Evaluate Neoadjuvant Osimertinib for Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer.
    2019 | P1.14-58 A Phase II Study to Evaluate Neoadjuvant Osimertinib for Surgically Resectable, EGFR-Mutant Non-Small Cell Lung Cancer.
    ' href="https://researcherprofiles.org/profile/79291379">UCSF Research Profile
  45. Differential gene expression identifies KRT7 and MUC1 as potential metastasis-specific targets in sarcoma.
    2019 | PubMed
  46. Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging.
    2019 | PubMed
  47. Applications of Next-Generation Sequencing in Neoantigen Prediction and Cancer Vaccine Development.
    2019 | PubMed
  48. Quantitative Polymerase Chain Reaction for Companion Diagnostics and Precision Medicine Application.
    2019 | Quantitative Polymerase Chain Reaction for Companion Diagnostics and Precision Medicine Application.
    ' href="https://researcherprofiles.org/profile/214924777">UCSF Research Profile
  49. Central Airway Obstruction Due to Tracheal Glomus Tumor.
    2018 | PubMed
  50. Giant right coronary artery aneurysm presenting as cardiac tamponade.
    2018 | PubMed
  51. P2.16-12 Expanded Data Confirm Molecular Testing Identifies Lung Adenocarcinoma Patients, Including Stage IA, Who Benefit from Adjuvant Chemotherapy.
    2018 | P2.16-12 Expanded Data Confirm Molecular Testing Identifies Lung Adenocarcinoma Patients, Including Stage IA, Who Benefit from Adjuvant Chemotherapy.
    ' href="https://researcherprofiles.org/profile/79294728">UCSF Research Profile
  52. P3.03-24 Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging.
    2018 | P3.03-24 Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging.
    ' href="https://researcherprofiles.org/profile/79291992">UCSF Research Profile
  53. Propensity Matched Analysis of Perioperative Outcomes in Robotic-Assisted Thoracic Surgery, Video Assisted Thoracic Surgery, and Open Lung Resections.
    2018 | Propensity Matched Analysis of Perioperative Outcomes in Robotic-Assisted Thoracic Surgery, Video Assisted Thoracic Surgery, and Open Lung Resections.
    ' href="https://researcherprofiles.org/profile/79291991">UCSF Research Profile
  54. Intraoperative identification and treatment of a giant right coronary artery aneurysm.
    2018 | PubMed
  55. Surgical Management of Pulmonary Mucormycosis in Third-Trimester Pregnancy.
    2018 | PubMed
  56. Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung Cancer.
    2017 | PubMed
  57. Management of Lung Cancer Invading the Superior Sulcus.
    2017 | PubMed
  58. OA19.06 Adjuvant Chemotherapy Decisions Based on Molecular Risk Status Improves Outcomes in Early Stage, Non-Small Cell Lung Cancer.
    2017 | OA19.06 Adjuvant Chemotherapy Decisions Based on Molecular Risk Status Improves Outcomes in Early Stage, Non-Small Cell Lung Cancer.
    ' href="https://researcherprofiles.org/profile/79292724">UCSF Research Profile
  59. P1.03-066 Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer TNM Staging Topic: Staging.
    2017 | P1.03-066 Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer TNM Staging Topic: Staging.
    ' href="https://researcherprofiles.org/profile/79294727">UCSF Research Profile
  60. High risk, high reward: An analysis of outcomes for candidates awaiting hepatic re-transplantation.
    2016 | PubMed
  61. High risk, high reward: An analysis of outcomes for candidates awaiting hepatic re-transplantation.
    2016 | PubMed
  62. Wnt7A is a putative prognostic and chemosensitivity marker in human malignant pleural mesothelioma.
    2015 | PubMed
  63. The race to liver transplantation: a comparison of patients with and without hepatocellular carcinoma from listing to post-transplantation.
    2015 | PubMed
  64. Prognostic and Predictive Biomarker Signatures.
    2014 | Prognostic and Predictive Biomarker Signatures.
    ' href="https://researcherprofiles.org/profile/79291033">UCSF Research Profile
  65. The migrated liver transplantation candidate: insight into geographic disparities in liver distribution.
    2014 | PubMed
  66. Analytical validation of a practical molecular assay prognostic of survival in nonsquamous non-small cell lung cancer.
    2013 | PubMed
  67. International trial of adjuvant therapy in high risk stage I non-squamous cell carcinoma identified by a 14-gene prognostic signature.
    2013 | PubMed
  68. Prognostic assay in small, node-negative non-small cell lung cancer--reply.
    2013 | PubMed
  69. The role of stem cells in airway repair: implications for the origins of lung cancer.
    2012 | PubMed
  70. A prognostic assay to identify patients at high risk of mortality despite small, node-negative lung tumors.
    2012 | PubMed
  71. Development of a rapid and practical mutation screening assay for human lung adenocarcinoma.
    2012 | PubMed
  72. A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies.
    2012 | PubMed
  73. IL11 is prognostic of survival in lung adenocarcinoma.
    2011 | IL11 is prognostic of survival in lung adenocarcinoma.
    ' href="https://researcherprofiles.org/profile/79295340">UCSF Research Profile
  74. Child neurology: Brachial plexus birth injury: what every neurologist needs to know.
    2011 | PubMed
  75. Downregulation of EMX2 is associated with clinical outcomes in lung adenocarcinoma patients.
    2011 | PubMed
  76. Cancer stem cells in lung tumorigenesis.
    2010 | PubMed
  77. Genomic prognostic models in early-stage lung cancer.
    2009 | PubMed
  78. Anal canal duplication associated with presacral cyst.
    2008 | PubMed
  79. Integration of flow-dependent endothelial phenotypes by Kruppel-like factor 2.
    2005 | PubMed
  80. Fluid Mechanical Forces as Extrinsic Modifiers of Endothelial Function.
    2005 | Fluid Mechanical Forces as Extrinsic Modifiers of Endothelial Function.
    ' href="https://researcherprofiles.org/profile/79295135">UCSF Research Profile
  81. Clinical pulmonary autograft valves: pathologic evidence of adaptive remodeling in the aortic site.
    2004 | PubMed
  82. Catalysis of peptide dissociation from class II MHC-peptide complexes.
    1999 | PubMed